Literature DB >> 2523818

O- and N-glycosylation lead to different molecular mass forms of human monocyte interleukin-6.

V Gross1, T Andus, J Castell, D Vom Berg, P C Heinrich, W Gerok.   

Abstract

The biosynthesis and secretion of human interleukin-6 (IL-6) was studied in monocyte cultures stimulated with endotoxin. After labeling with [35S]methionine and immunoprecipitation with a specific antiserum one major (24 kDa) and four minor (27.5, 23.3, 22.5 and 21.8 kDa) molecular mass forms of IL-6 could be found in the cells and media. Incubation of monocyte media with sialidase and subsequently with endo-alpha-N-acetylgalactosaminidase, which cleaves Gal(beta 1-3)Gal-NAc from serine or threonine, led to the formation of only two forms of IL-6 with apparent molecular masses of 25 and 21.8 kDa. The latter had an electrophoretic mobility indistinguishable from that of 125I-labeled recombinant human IL-6. The results suggest that human monocyte IL-6 carries O-glycosidically bound carbohydrates with a Gal(beta 1-3)Gal-NAc core to which only sialic acid is bound. Differences in O-glycosylation are the major cause for the molecular heterogeneity of IL-6. A small part of IL-6 (27.5 kDa form) is in addition N-glycosylated. Incubation of monocytes with tunicamycin and 1-deoxymynnojirimycin and treatment of IL-6 with endoglucosaminidase H suggested that the 27.5 kDa form of IL-6 carries at least one N-linked complex-type oligosaccharide chain.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2523818     DOI: 10.1016/0014-5793(89)81361-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  13 in total

1.  Regulation of interleukin-6 expression in human decidual cells and its potential role in chorioamnionitis.

Authors:  Charles J Lockwood; William K Murk; Umit A Kayisli; Lynn F Buchwalder; S Joseph Huang; Felice Arcuri; Min Li; Arun Gopinath; Frederick Schatz
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

Review 2.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

Review 3.  Adipocyte-derived hormones, cytokines, and mediators.

Authors:  Cristina M Rondinone
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

4.  Development and validation of panoptic Meso scale discovery assay to quantify total systemic interleukin-6.

Authors:  Shalini Chaturvedi; Derick Siegel; Carrie L Wagner; Jaehong Park; Helgi van de Velde; Jessica Vermeulen; Man-Cheong Fung; Manjula Reddy; Brett Hall; Kate Sasser
Journal:  Br J Clin Pharmacol       Date:  2015-06-04       Impact factor: 4.335

Review 5.  Interleukin-6: structure-function relationships.

Authors:  R J Simpson; A Hammacher; D K Smith; J M Matthews; L D Ward
Journal:  Protein Sci       Date:  1997-05       Impact factor: 6.725

Review 6.  Interleukin-6 and its receptor during homeostasis, inflammation, and tumor growth.

Authors:  J Bauer
Journal:  Klin Wochenschr       Date:  1989-07-17

7.  Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea.

Authors:  S Nicholls; S Stephens; C P Braegger; J A Walker-Smith; T T MacDonald
Journal:  J Clin Pathol       Date:  1993-08       Impact factor: 3.411

8.  Preeclampsia-related inflammatory cytokines regulate interleukin-6 expression in human decidual cells.

Authors:  Charles J Lockwood; Chih-Feng Yen; Murat Basar; Umit A Kayisli; Maritza Martel; Irina Buhimschi; Catalin Buhimschi; S Joseph Huang; Graciela Krikun; Frederick Schatz
Journal:  Am J Pathol       Date:  2008-05-08       Impact factor: 4.307

9.  Inhibition of protein N-glycosylation by 2-deoxy-2-fluoro-D-galactose.

Authors:  V Gross; W E Hull; U Berger; T Andus; W Kreisel; W Gerok; D Keppler
Journal:  Biochem J       Date:  1992-08-01       Impact factor: 3.857

10.  Regulation of interleukin-6 (IL-6) expression: evidence for a tissue-specific role of protein kinase C.

Authors:  V Gross; B Zhang; Y Geng; P M Villiger; M Lotz
Journal:  J Clin Immunol       Date:  1993-09       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.